Role of TIM-3 in ovarian cancer
Authors:
- 29 March 2017
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 19 (9) , 1079-1083
Abstract
Evidences have suggested that immunotherapy for ovarian cancer is effective. Immune checkpoints have emerged in the field of cancer immunotherapy. Multiple studies have shown negative regulation of TIM-3 expression on CD4+ and CD8+ T cells and other immunocytes. Overexpression of TIM-3 in innate immune cells has been found in certain types of tumor. The blockade of TIM-3 leads to sustained anti-tumor reactions. TIM-3 plays an inhibitive role for immunity in ovarian cancer. TIM-3 is involved in the development of various subtypes of ovarian cancer and thus has the potential to be a therapeutic target for treatment of ovarian cancer.Keywords
Funding Information
- Society Development Plans, Department of Science and Technology Changzhou (CJ20159018)
This publication has 50 references indexed in Scilit:
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ TregsJournal of Clinical Investigation, 2012
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicityBlood, 2012
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaJournal of Clinical Investigation, 2012
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1Cancer Research, 2012
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood, 2011
- Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 familyImmunological Reviews, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsJournal of Experimental Medicine, 2010
- TIMs: central regulators of immune responsesJournal of Experimental Medicine, 2008